IONIS PHARMACEUTICALS, INC. (IONS): what the price assumes

In the published model solve dated 2026-Q2, anchored at $55.18, IONIS PHARMACEUTICALS, INC. (IONS) is priced for +17.0% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-07-29 · Exported: 2026-08-01 · Source: https://boothcheck.com/report/IONS

Headline

FieldValue
TickerIONS
CompanyIONIS PHARMACEUTICALS, INC.
Current price$55.18/sh
CompositionTRYNGOLZA sales, net 11% / DAWNZERA sales, net 1% / SPINRAZA royalties 22% / WAINUA royalties 5% / Other royalties 3% / Other commercial revenue 4% / Collaborative agreement revenue 49% / WAINUA joint development revenue 4%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisrevenue-multiple
EV / sales paid10.3x
Steady-state operating margin assumed32.6%
Implied growth17.0%

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 7.5% cost of capital with 4% terminal growth over a 5-year stage, holding a 32.6% terminal operating margin (the 75th percentile of its own demonstrated operating margins); each 1pp of cost of capital moves the implied revenue growth ~8.9pp.

Reconcile: at the x-ray's 9.3% required return this reads ~6.5 years; the models below use their own rates.

How unusual the bet is: within-range

ReferenceValue
vs own history+0.16σ
sustained it ~5 years at this level45%
implied end-window share0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset18.52x1expensive
Earnings—0—
Relative2.15x2expensive
Growth1.94x2expensive

Families that call it expensive: Asset, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.3%); the inversion above states its own rate.

Per-Model Detail (n=5)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$0.00—noNegative/zero FCF — equity value floored at $0
DCF Exit MultipleGrowth$0.00—noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative$25.672.15xyesP/S fallback (negative EPS): Sector P/S 4.0x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$2.9818.52xyesBook value floor: BV/sh $2.98, ROE negative
Two-Stage Excess ReturnAsset$2.6820.59xyesBook value with convergence: BV/sh $2.98, ROE converges to ke (excluded from median)
Discounted Future Market CapGrowth$63.780.87xyesRev $1.1B, growth 30% (input: historical growth; tapered), Terminal P/S: 6.9x / 8.6x / 10.3x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth$18.313.01xyesMargin ramp: -31% → 12% over 7yr, rev growth 30% (input: historical growth; tapered)
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$25.672.15xyesRevenue $1.06B × sector P/S 4.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net cash$106.7m
Interest coverage-19.2x
Share count CAGR (dilution)3.9%
Burning cashyes

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Bullet Takeaways

Bull Case

One number frames the entire bull case: greater than $3 billion. That is the U.S. peak-sales estimate management now assigns to TRYNGOLZA across its approved and expansion indications, raised from greater than $2 billion. For a company whose total trailing revenue is a fraction of that, a single wholly-owned drug with multi-billion peak potential is the difference between a perpetual research shop and a self-funding commercial biotech. The bull case is that Ionis has crossed from one to the other.

The platform underneath is the reason the pipeline is deep rather than dependent on one shot. Antisense and RNA-targeted technology lets Ionis design medicines against targets that traditional drugs cannot reach, and the company has spent decades turning that into an industry-leading pipeline. The proof is the cadence: Ionis is on track for three independent medicines on the market in 2026, with olezarsen in severe hypertriglyceridemia expected around its mid-year regulatory date and zilganersen in Alexander's disease expected later in the year. DAWNZERA, the first RNA-targeted prophylactic for hereditary angioedema, is already launched and guided to $110 million to $120 million of product sales in 2026. These are not pipeline hopes; they are products reaching the market on schedule.

The financial inflection is visible in the most recent quarter. Total revenue nearly doubled to $246.1 million from $131.6 million a year earlier, driven by the new launches and collaboration milestones, and the company raised full-year revenue guidance by $75 million. The model is shifting from collecting royalties on partners' drugs, the Spinraza era, to keeping the full economics of its own launches. If the launch curves bend the way management projects, the operating loss converts to profit, and a company with a proven platform and owned commercial assets is worth far more than the same company selling its science to partners.

Bear Case

The bear case starts not with a ratio but with a plain observation: Ionis does not yet make money, and the price is paying as if the turn to profitability is a formality rather than a question. The company ran a trailing operating loss of more than $350 million and continues to burn cash. The drugs are launching, but launching a drug and scaling it into billions of dollars of profitable revenue are separated by years of commercial execution, payer negotiations, and competition, and the market is pricing the destination, not the journey.

That is what the methods show. No family of valuation, asset value, earnings power, peer multiples, or even forward growth, reaches the current price. The price-to-fundamentals disconnect is total: there are no current earnings to anchor an earnings method, and the revenue-multiple and growth methods that do apply still land below the price. Translated, the buyer is paying for a forward revenue ramp steep enough that even optimistic growth assumptions do not close the gap on today's numbers. When every method says expensive and the price holds anyway, the price is a bet beyond what any standard frame supports, riding entirely on the launches hitting their projected curves.

The competition is real and named in the company's own disclosure, which lists "medicines that compete or may compete directly with our marketed medicines and late-stage medicines" across efficacy, dosing, price, and reimbursement. A novel drug rarely launches into an empty field; it launches against incumbents and fast-followers. The offsetting comfort is the balance sheet: Ionis holds net cash of roughly $107 million and has the partnership royalties to lean on, so this is not an imminent-insolvency story. It is a valuation-and-execution bear: the science is proven, the price assumes the commercialization is too, and that part is still being written.

Valuation

Ionis is a company in transition, and its valuation can only be read forward, because the trailing numbers describe the old model and the price describes the new one. The price embeds an assumption of roughly 20% revenue growth sustained while margins swing from deeply negative to positive, the path of a research company becoming a profitable commercial one. That is the bet, and it is a specific, demanding one.

The methods make the demand explicit. No family reaches the current price. With a trailing operating loss, the earnings-power and asset-based lenses produce nothing usable, and the revenue-multiple and forward-growth methods, the only ones that apply to a pre-profit launcher, still land below the price. The price sits above even the growth lens, which means the market is crediting a steeper or longer ramp than a standard forward model will underwrite. That spread between price and every method is the launch premium: the value the market assigns to TRYNGOLZA, DAWNZERA, and the 2026 approvals reaching their projected scale before the standard frames can see it in the financials.

Solvency is the floor that keeps the bet alive while it plays out. Net cash of about $107 million plus the legacy partnership royalties give Ionis runway to fund the launches without an immediate, dilutive raise, though the share count has crept up nearly 4% a year. The cash is not a fortress, but it is enough to bridge to the inflection if the launches perform. The decisive variable is not on the balance sheet; it is the slope of the launch curves. The price already credits them; the prints have to deliver them.

Catalysts

The most recent quarter, the first of 2026, was a clean beat that prompted a guidance raise. Total revenue reached $246.1 million, up from $131.6 million a year earlier, driven by new product launches and collaboration milestones, and the company lifted full-year 2026 revenue guidance by $75 million to a range of $875 million to $900 million while improving its non-GAAP operating-loss guidance.

The near-term catalysts are regulatory and concrete. Ionis is on track for three independent medicines on the market in 2026: olezarsen for severe hypertriglyceridemia, expected around its mid-year regulatory decision, and zilganersen for Alexander's disease, expected at its decision later in the year. Each approval expands the wholly-owned commercial portfolio and reduces the company's dependence on partnership economics.

The launch ramps are the recurring scorecard. TRYNGOLZA generated $108 million in its first year and now carries a U.S. peak-sales estimate above $3 billion, while DAWNZERA is guided to $110 million to $120 million of product sales in 2026. Each subsequent quarter is a referendum on whether those curves are bending toward the multi-billion potential management projects or settling at a more modest level.

Peer Cohorts (Per Segment, With Filing Citations)

Ionis operations (single segment) (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Ionis Q1 2026 earnings call · Ionis Q1 2026 earnings release

View the full interactive IONS report on boothcheck